<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9835">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01797705</url>
  </required_header>
  <id_info>
    <org_study_id>DHC-002</org_study_id>
    <nct_id>NCT01797705</nct_id>
  </id_info>
  <brief_title>Revised Algorithm for Next Generation DeVilbiss Healthcare AutoAdjust Continuous Positive Airway Pressure (CPAP)</brief_title>
  <official_title>Revised Algorithm for Next Generation DeVilbiss AutoAdjust CPAP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DeVilbiss Healthcare LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DeVilbiss Healthcare LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to improve the current FDA-approved continuous positive
      pressure auto-titration algorithm, including treatment precision, residual disease detection
      characteristics and phenotyping with the DeVilbiss brand AutoAdjust CPAP device.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>The purpose of this protocol is to improve the current FDA-approved continuous positive pressure auto-titration algorithm, including treatment precision, residual disease detection characteristics and phenotyping.</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The purpose of this protocol is to improve the current FDA-approved continuous positive pressure auto-titration algorithm, including treatment precision, residual disease detection characteristics and phenotyping. The study will categorize sleep apnea subjects as &quot;obstructive&quot; vs. &quot;chemoreflex mediated&quot; in a dichotomous manner, compared to phenotyping using conventional polysomnography and AASM (american association of sleep medicine) 2012 scoring/phenotyping. Efficacy will determine concordance with human manual titration decisions, with success defined as 80% concordance of decisions in stable and unstable NREM (non-rapid eye movement) sleep, and supine REM (rapid eye movement) sleep.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Expert Reviewer's Assessment/DeVilbiss AutoAdjust CPAP device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DeVilbiss AutoAdjust CPAP</intervention_name>
    <arm_group_label>Expert Reviewer's Assessment/DeVilbiss AutoAdjust CPAP device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Apnea hypopnea index â‰¥ 10 / hour of sleep on the diagnostic polysomnogram (or
             diagnostic component of a split night polysomnogram)

          -  Compliant use (averaging 4 or more hours nightly)

          -  Age 21-64 years

        Exclusion Criteria:

          -  Congestive heart failure

          -  Chronic obstructive lung disease requiring supplemental oxygen

          -  Chronic renal failure stroke

          -  Neurodegenerative disorders

          -  Uncontrolled psychiatric illnesses.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NeuroCare, Inc.</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J Thomas, MD</last_name>
      <phone>617-667-5864</phone>
      <email>rthomas1@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
